Volume 22, Issue 1, Pages 9-18 (January 2005)

Slides:



Advertisements
Similar presentations
Manifestation of Novel Social Challenges of the European Union in the Teaching Material of Medical Biotechnology Master’s Programmes at the University.
Advertisements

November 2, IMMUNITY ADAPTIVEINNATE CELL MEDIATEDHUMORAL ANTIBODIES EFFECTOR SYSTEMS Fc Receptors Complement RECEPTORS EFFECTORS Cells Molecules.
CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma  André Veillette, Huaijian Guo  Critical Reviews.
Immune Receptors and Signal Transduction
B Cell Receptor Signalling
Molecular regulation of mast cell activation
Eph-Ephrin Bidirectional Signaling in Physiology and Disease
Ali A Khorasani Bethany Bennett Jenna Rozacky November 21, 2011
Volume 100, Issue 1, Pages (January 2000)
The CD19–CD21 Complex Regulates Signal Transduction Thresholds Governing Humoral Immunity and Autoimmunity  Thomas F Tedder, Makoto Inaoki, Shinichi Sato 
SHIP Recruitment Attenuates FcγRIIB-Induced B Cell Apoptosis
Why Is There so Much CD45 on T Cells?
Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect by Sherif S. Farag, Todd A. Fehniger, Loredana Ruggeri, Andrea.
Signaling molecules as therapeutic targets in allergic diseases
Volume 73, Issue 5, Pages (March 2008)
Mechanisms of mast cell signaling in anaphylaxis
Figure 1 Therapeutic targeting of the B-cell receptor (BCR)
T-cell activation through the antigen receptor
Molecular regulation of mast cell activation
Ana C. Anderson, Nicole Joller, Vijay K. Kuchroo  Immunity 
Unraveling the Pros and Cons of Interferon-γ Gene Regulation
EGFR T790M Mutation: A Double Role in Lung Cancer Cell Survival?
Steve Burden, Yosef Yarden  Neuron 
Great Expectations for PIP: Phosphoinositides as Regulators of Signaling During Development and Disease  Lara C. Skwarek, Gabrielle L. Boulianne  Developmental.
Micromanaging Memory with Immunoglobulin Microclusters
Philip P. Ostrowski, Sergio Grinstein, Spencer A. Freeman 
PKB Binding Proteins Cell
TIGIT-CD155 Interactions in Melanoma: A Novel Co-Inhibitory Pathway with Potential for Clinical Intervention  Karsten Mahnke, Alexander H. Enk  Journal.
Positive Regulation of Lyn Kinase by CD148 Is Required for B Cell Receptor Signaling in B1 but Not B2 B Cells  Katarzyna M. Skrzypczynska, Jing W. Zhu,
The pathophysiology of anaphylaxis
Silvia Bolland, Roger N Pearse, Tomohiro Kurosaki, Jeffrey V Ravetch 
Met as a therapeutic target in HCC: Facts and hopes
Volume 8, Issue 4, Pages (April 1998)
The CD19–CD21 Complex Regulates Signal Transduction Thresholds Governing Humoral Immunity and Autoimmunity  Thomas F Tedder, Makoto Inaoki, Shinichi Sato 
Signaling Network Model of Chromatin
Fabiola Osorio, Caetano Reis e Sousa  Immunity 
Fernando Elijovich, Cheryl L. Laffer  Kidney International 
RAS Proteins and Their Regulators in Human Disease
MicroRNA Control in the Immune System: Basic Principles
AKT/PKB Signaling: Navigating the Network
Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family
Plasma Cells for Hire: Prior Experience Required
SCL: From the origin of hematopoiesis to stem cells and leukemia
Naomi E. Harwood, Facundo D. Batista  Immunity 
Volume 17, Issue 2, Pages (January 2007)
AKT/PKB Signaling: Navigating Downstream
SHIP, SHIP2, and PTEN activities are regulated in vivo by modulation of their protein levels: SHIP is up-regulated in macrophages and mast cells by lipopolysaccharide 
Signalling links in the liver: Knitting SOCS with fat and inflammation
Volume 10, Issue 5, Pages (November 2002)
SOCS Proteins, Regulators of Intracellular Signaling
The suppressors of cytokine signaling (SOCS) proteins
Antigen-Receptor Signaling to Nuclear Factor κB
LAT Links the Pre-BCR to Calcium Signaling
Alexander Kiani, Anjana Rao, Jose Aramburu  Immunity 
Regulatory B Cells: Origin, Phenotype, and Function
Janna Krueger, Christopher E. Rudd  Immunity 
Volume 13, Issue 1, Pages (July 2000)
T Cell Anergy: Where It's LAT
Volume 10, Issue 4, Pages (April 1999)
Volume 104, Issue 4, Pages (February 2001)
Vladimir A. Botchkarev  Journal of Investigative Dermatology 
Sites and Stages of Autoreactive B Cell Activation and Regulation
Vanessa L. Ott, PhD, John C. Cambier, PhD 
Cross-regulation of Signaling Pathways by Interferon-γ: Implications for Immune Responses and Autoimmune Diseases  Xiaoyu Hu, Lionel B. Ivashkiv  Immunity 
The Transcriptional Regulation of B Cell Lineage Commitment
Volume 7, Issue 1, Pages 1-11 (July 1997)
Yang Cang-Jin , Zhang Chi , Lu Yang-Ning , Jin Jia-Qi , Wang Xue-Lu  
Brief Review – Growth Factors and Receptors
Cell Signaling by Receptor Tyrosine Kinases
Successful targeting of ErbB2 receptors—is PTEN the key?
Presentation transcript:

Volume 22, Issue 1, Pages 9-18 (January 2005) Lyn Tyrosine Kinase  Yuekang Xu, Kenneth W. Harder, Nicholas D. Huntington, Margaret L. Hibbs, David M. Tarlinton  Immunity  Volume 22, Issue 1, Pages 9-18 (January 2005) DOI: 10.1016/j.immuni.2004.12.004

Figure 1 Lyn Structure and Mode of Regulation Lyn is both myristylated and palmitylated localizing it to lipid rafts within the plasma membrane (indicated by the lighter shading of the plasma membrane). All SFKs are held in an inactive state through phosphorylation of a tyrosine residue in their C-terminal regulatory (R) domain by Csk family enyzmes. Csk is itself regulated by membrane localization through interaction with PAG/Cbp. Phosphorylation of the C-terminal tyrosine in SFKs holds the enzymes in a closed conformation through SH2 domain interactions. Lyn can be activated by dephosphorylation of the C-terminal regulatory tyrosine by CD45. CD45 is shown within the lipid raft and acting to dephosphorylate Y508 for graphic purposes. Its location varies over time and it is also able to dephosphorylate Y397, inhibiting SFK activity (Ashwell and D'Oro, 1999). Immunity 2005 22, 9-18DOI: (10.1016/j.immuni.2004.12.004)

Figure 2 Scheme of B Cell Development and the Importance of Lyn and Lyn-Regulated Proteins in this Process Conventional B cells arise from fetal liver and adult BM, whereas B1a B cells originate in fetal omentum and are thought to play an important role in innate immunity, secreting large amounts of low-affinity IgM antibody. CD45 and CD19 are required for B1 B cell development, and constitutively active Lyn expands this compartment. SFK are critical for conventional B cell development beyond the pro-B cell stage as lyn−/−fyn−/−blk−/− mice are blocked at this point. Lyn and Lyn targets have important and unique roles beyond the immature B cell developmental stage, arrows show where they enhance and bars where they inhibit a developmental step. Lyn is also critical for tempering plasma cell differentiation as lyn−/− mice show increased frequency of plasma cells. Marginal zone (MZ) B cell generation is blocked in both lyn−/− and lynup/up mice. Immunity 2005 22, 9-18DOI: (10.1016/j.immuni.2004.12.004)

Figure 3 Schematic Representation of Signal Transduction Pathways Modulated by Lyn in B Cells Lyn contributes to positive regulation of signaling through tyrosine phosphorylation of ITAMs in the Igα and Igβ components of the BCR and in CD19. This role can be assumed by other SFKs such as Fyn and Blk, and promotes B cell activation through the recruitment of Syk and PI3K. Lyn plays an essential role in negative regulation of signaling through its unique ability to phosphorylate ITIMs in inhibitory cell surface receptors such as FcγRIIb1, CD22, PIR-B, and CD5 and a potential inhibitory site on Syk (see text). Whether CD72, PAG, and PD-1 are Lyn targets in vivo has yet to be confirmed. Positive phosphorylation of Syk is redundant with other SFKs. ITIM phosphorylation induces the recruitment of inhibitory phosphatases such as SHP-1/2 and SHIP-1, which down modulate signaling. Lyn is also suspected to be critical for the phosphorylation of PAG/Cpb in B cells, thereby enabling Csk recruitment to the plasma membrane where it may modulate SFK activity. Squares, SH3 domains; circles, SH2 domains; and −P, phospho tyrosines. The single −P on each inhibitory receptor is indicative and not a representation of the true target number. Immunity 2005 22, 9-18DOI: (10.1016/j.immuni.2004.12.004)